Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Other Non Operating Income (2024 - 2025)

Prelude Therapeutics' Other Non Operating Income history spans 2 years, with the latest figure at $891000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 82.53% year-over-year to $891000.0; the TTM value through Dec 2025 reached $5.1 million, down 59.59%, while the annual FY2025 figure was $5.1 million, 59.59% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $891000.0 at Prelude Therapeutics, up from $693000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $5.1 million in Q4 2024 and bottomed at $693000.0 in Q3 2025.